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ANTIBACTERIAL EFFECT OF CURCUMINOID SILICA NANOPARTICLE TO 
ESCHERICHIA COLI BACTERIA 
 
Bobby Hendrawan1), Bernadette D Novita2), Adi P Hendrata3) 
 
ABSTRACT 
Background: Escherichia coli is one of the main bacteria that cause urinary tract infection. In 
the past few years, Escherichia coli’s susceptibility to antibiotic has been decreased and 
causing antibiotic resistance. Furthermore, Curcuma longa plant has been used daily by the 
population as a cooking spice, and evidently has an antibacterial effect on some bacteria such 
as Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. Curcumin as the 
active ingredients of Curcuma longa has a low water solubility and poor absorption so that 
silica nanoparticle usage will help the solubility and absorption problem of Curcumin.  
Aim: This study aimed to know the antibacterial effect of Curcuminoid silica nanoparticles to 
Escherichia coli.  
Methods: This research is an in vitro experimental study and checking by using a 
microdilution method and observed with a spectrophotometer.  
Results: There is 60,6% inhibition obtained at 1000 µg/mL. MIC and MBC were not 
obtained at 62,5 µg/mL to 32000 µg/mL.  
Conclusion: Curcuminoid silica nanoparticles has no antibacterial effect against Escherichia 
coli.  
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INTRODUCTION 
 
Escherichia coli becomes the main 
bacteria that causing either upper or lower 
urinary tract infection.(1) Escherichia coli 
is a normal flora from the intestine and can 
be pathogenic when the host cell changed 
or exposed to another area of the body.(2,3) 
In the last few years, Escherichia coli 
simultaneously decreased its susceptibility 
to Ceftazidime and Ciprofloxacin from 
62,5% in 2006 to 48,7% in 2012.(4) 
Escherichia coli is increasing in resistance 
case to Ciprofloxacin from 0,5% to 15,3%, 
Trimethoprim increasing from 13,3% to 
46%, and Nitrofurantoin from 0% to 5,6% 
from 2008 to 2014 and resistance to 
Ampicillin and Trimethoprim-
Sulfamethoxazole.(5,6) Escherichia coli 
caused the greatest susceptibility 
decreasing to Ciprofloxacin comparing to 
another antibiotics.(7)  
Curcuma longa is one of 
Zingiberaceae family that can be used for 
medicine. Curcuma longa grows in the 
subtropical area to the tropical area.(8) 
Besides used for cooking spices, Curcuma 
longa also used for traditional medicine in 
Asian countries like India, Bangladesh, 
and Pakistan.(9) Curcuma longa benefits 
for pulmonary diseases, gastrointestinal 
diseases, and integument diseases.(10) A 
study reports that Curcuma longa extract 
has Curcumin as the active ingredient that 
has an antibacterial effect against 
Staphylococcus aureus, anti-inflammation, 
anti-cancer, and antioxidant, but Curcumin 
is a non-water-soluble, has low 
absorbance, rapid metabolism, and rapid 
systemic elimination.(11,12) 
Nanoparticle as drug delivery is a 
formulation of particle that disperses in 
nanometer size; study reports the effective 
size is under 100 nm.(13) Another study 
reports Curcuma longa nanoparticle 
extract has solubility 1936 times bigger 
than Curcuma longa extract only.(14) 
Curcuma longa extracts active ingredient 
like Curcumin has more benefits if used 
with nanoparticle.(14) The study aimed to 
know the effect of Curcumin that can be 
used to treat Escherichia coli infection. 
The researcher wanted to know the MIC 
and MBC of Curcuminoid Silica 
Nanoparticle to Escherichia coli. 
 
METHODS 
 
This study is an experimental study 
with a non-equivalent control group 
design. This study held at Balai Besar 
Laboratorium Kesehatan Surabaya, 
Microbiology laboratory facility of 
Medical Faculty Widya Mandala Catholic 
University Surabaya, and Research 
laboratory facility of Pharmacy Faculty 
Widya Mandala Catholic University 
Surabaya. The sample that used in this 
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study is Escherichia coli ATCC 25922 
from Balai Besar Laboratorium Kesehatan 
Surabaya. Research is divided into two 
parts. In the first part, a concentration that 
has been used is 62,5 – 1000 µg/mL and 
used four control groups:  
K1 = Mueller Hinton Broth. 
K2a-e = Mueller Hinton Broth + 
Curcuminoid Silica Nanoparticle 62,5 – 
1000 µg/mL 
K3 = Mueller Hinton Broth + Escherichia 
coli + tween 20 
K4 = Mueller Hinton Broth + Escherichia 
coli + Ciprofloxacin 
In the second part, concentration that has 
been used is 2000 – 32000 µg/mL with the 
same control groups. This study used two 
intervention groups:  
P0 = Mueller Hinton Broth + Escherichia 
coli 
P1-P5 = Mueller Hinton Broth + 
Escherichia coli + Curcuminoid Silica 
Nanoparticle    62,5 – 1000 µg/mL 
Second part is used the same intervention 
groups but with different concentration: 
P0 = Mueller Hinton Broth + Escherichia 
coli 
P1-P5 = Mueller Hinton Broth + 
Escherichia coli + Curcuminoid Silica 
Nanoparticle    2000 - 32000 µg/mL. 
 
Picture 1. Working map of 96-well microplate 
 
Curcuminoid Silica Nanoparticle 
preparation 
 
Curcuminoid Silica Nanoparticle in 
this study was made using absorption 
technique. 50 mg of Curcuminoid powder 
mix with 200 mg of Silica Nanoparticle 
and mix it in 20 ml ethanol. Mixture then 
put in a container. Container then put in a 
bath sonicator for 2 minutes sonication 
process. Ethanol then evaporated using 
rotary evaporator at 55˚C.  The final form 
is Curcuminoid Silica Nanoparticle 
powder.(15)  
Curcuminoid Silica Nanoparticle 
extract that made first is the highest 
concentration first   1000 µg/mL. To make 
1000 µg/mL we had to made threefold 
concentration that is 3000 µg/mL because 
it is easier to made the dilution and as a 
correction when we dilute the bacteria to 
make suspension in NaCl 0,9%. This 
dilution method is also used for the second 
part of this research. After we made the 
threefold concentration, we made the 
mixture from 100 µl Mueller Hinton Broth 
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and 100 µl Curcuminoid Silica 
Nanoparticle. This mixture then put in a 
test tube that has been filled with 100 µl 
Mueller Hinton Broth. This step was 
repeated to the lowest concentration; then 
we put the bacteria in same size 50 µl. 
 
Picture 2. Inhibitory percentage 
 
Bacteria test preparation 
 
Bacteria that have been identified then 
made for suspension to use in 
microdilution process. This bacteria 
suspension made by mix the bacteria with 
NaCl 0,9%. Turbidity is adjusted with 0,5 
McFarland standard. 0,5 McFarland 
standard is made by mixing 0,05 mL 
BaCl2 1% with 9,95mL H2SO4 1%. 
 
RESULT 
 
Table 1. Optical Density 
 
Optical Density was determined using 
spectrophotometer shows that there was 
declining Optical Density between each 
concentration in the first part of this 
research. Second part of this research did 
not measure the Optical Density but using 
inoculation in Mueller Hinton Agar. 
Picture 2 shows there is increasing 
inhibitory percentage from first 
intervention to the fifth intervention. First 
and second intervention has a mean 
inhibitory percentage of 38%, third 
intervention has 43,2%, fourth intervention 
has 50,2%. The fifth intervention is the 
highest percentage of 60,6%.  
Inoculation of control groups in Mueller 
Hinton Agar have been done after Optical 
Density determined.  Picture 3a in K4 part 
shows there’s no bacteria grown in 
antibiotic control; it shows there was no 
contamination when inoculation process. 
Picture 3a in part K1 shows there was no 
contamination in media Mueller Hinton 
Agar. Picture 3b shows there was no 
bacteria growth meaning there was no 
contamination in the extract. Inoculation 
result shows in intervention 1 to 
intervention 5, bacteria still grow in 
Mueller Hinton Agar (Picture 3c). On the 
second part, intervention 1 to intervention 
5 (2000 – 32000 µg/mL) also shows the 
same result; there was growth of the 
Mean Inhibitory Percentage 
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bacteria in Mueller Hinton Agar (Picture 
3d).		 			
DISCUSSION 
Several things are suspected to affect 
MIC and MBC result including bacteria 
factor and Curcuminoid Silica 
Nanoparticle extract, such as: 
 
 Escherichia coli factor 
The first factor from the bacteria is Outer 
Membrane of Escherichia coli which 
function of this two layer of 
lipopolysaccharides is as protection 
membrane. Cell wall of Gram Negative’s 
peptidoglycan is thinner than the Gram 
Positive’s peptidoglycan, but this outer 
membrane feature of Gram-negative 
bacteria helps protection function of the 
Gram Negative bacteria.(16) It caused by 
porin in outer membrane which function is 
to protect the bacteria against hydrophobic 
structure like Curcuminoid Silica 
Nanoparticle extract. Porin plays role to 
help diffusion of only hydrophilic structure 
because most of nutrition for bacteria is on 
hydrophilic structure, so porin will rule out 
hydrophobic structure (17), and make the 
extract cannot work properly. Different 
with Gram-Positive bacteria, Curcumin’s 
MIC on Gram Negative bacteria is greater 
(12), it is caused by the difference in 
bacteria structure and morphology 
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between Gram Positive and Gram 
Negative bacteria, shows the difference in 
MICSecond factor caused by Escherichia 
coli bacteria is flagella function that has 
the ability to do chemotaxis to avoid 
chemical material that harm the bacteria. It 
is started by chemical receptor response in 
outer cell then transmitted to the flagellar 
motor causing bacteria movement using its 
flagella avoiding the ‘harmful’ chemical 
substance that already detected (18), so 
antibacterial effect of Curcuminoid Silica 
Nanoparticle is not powerful enough.  
 
Curcuminoid Silica Nanoparticle factor 
Factor from the Curcuminoid Silica 
Nanoparticle is because there is a 
difference in extract making procedure 
from the previous study. The previous 
research is using wet-milling technique, so 
Curcumin size is smaller than this 
research, which is 2-40 mm only (12), while 
in this study using 100 nm. Another study 
used aqueous extract of Curcuma longa 
determined MIC at 4 mg/mL (19) because 
the technique that they used was different 
with this study.  
Curcuminoid extract storage also 
affects the extract. This is because 
Curcumin structure has photosensitivity so 
extract storage is also important (20). This 
research was already stored the extract in 
aluminum foil wrapped glass bottle to 
avoid light exposure. Besides that, when 
we worked also using a biosafety cabinet 
with lamp turned off. Light exposure 
factor is still can affect this research when 
we did weight measurement on the extract. 
Another factor is heating exposure 
when extract making process. Mixing 
extract with the nanoparticle is happened 
at 55˚C (21). This is because thermolabile 
character of the extract when expose to 
pH=7, but more stable in pH=3 (21), so it 
can affect the extract by reduce Curcumin 
retention, while Escherichia coli bacteria 
produce acidic metabolism waste (2).  
This study using nanoparticle 
characterization from the previous study 
because of device limitation so that 
effectiveness of nanoparticle cannot been 
analyzed. According to the previous study, 
silica nanoparticle size is 100 nm using 
TEM microscope, pore size is 10 nm, 
FTIR analysis shows peak at 3100 cm-1, it 
means there is hydrogen bond between 
silica nanoparticle and Curcumin (15). In 
vivo bioavailability in mice is showing 
that silica nanoparticle has higher 
bioavailability (0,0291 µg/mL) than 
Curcumin without silica nanoparticle 
(0,0105 µg/mL). In vitro release profile 
while using silica nanoparticle is also 
better than without nanoparticle. 
Cumulative release rate in Curcumin silica 
nanoparticle 12% and reaching plateau in 
48 hours, while Curcumin only has 4% 
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release rate and reaching plateau in 5 
hours22.  
 
CONCLUSION 
 
Curcuminoid silica nanoparticle extract 
has no antibacterial effect to Escherichia 
coli bacteria within concentration 62,5 - 
32000 µg/mL. 
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